BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1021 related articles for article (PubMed ID: 24938824)

  • 1. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease.
    Smart NA; Dieberg G; Ladhani M; Titus T
    Cochrane Database Syst Rev; 2014 Jun; (6):CD007333. PubMed ID: 24938824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review.
    Smart NA; Titus TT
    Am J Med; 2011 Nov; 124(11):1073-80.e2. PubMed ID: 22017785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary interventions for adults with chronic kidney disease.
    Palmer SC; Maggo JK; Campbell KL; Craig JC; Johnson DW; Sutanto B; Ruospo M; Tong A; Strippoli GF
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011998. PubMed ID: 28434208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antioxidants for chronic kidney disease.
    Jun M; Venkataraman V; Razavian M; Cooper B; Zoungas S; Ninomiya T; Webster AC; Perkovic V
    Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008176. PubMed ID: 23076940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
    Nistor I; Palmer SC; Craig JC; Saglimbene V; Vecchio M; Covic A; Strippoli GF
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD006258. PubMed ID: 25993563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease.
    Htay H; Johnson DW; Craig JC; Teixeira-Pinto A; Hawley CM; Cho Y
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD012899. PubMed ID: 33501650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
    Rabindranath KS; Strippoli GF; Daly C; Roderick PJ; Wallace S; MacLeod AM
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006258. PubMed ID: 17054289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid hormones for acute kidney injury.
    Nigwekar SU; Strippoli GF; Navaneethan SD
    Cochrane Database Syst Rev; 2013 Jan; (1):CD006740. PubMed ID: 23440810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral adsorbents for preventing or delaying the progression of chronic kidney disease.
    Wu HM; Sun HJ; Wang F; Yang M; Dong BR; Liu GJ
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD007861. PubMed ID: 25317905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for peritoneal dialysis-associated peritonitis.
    Ballinger AE; Palmer SC; Wiggins KJ; Craig JC; Johnson DW; Cross NB; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD005284. PubMed ID: 24771351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease.
    Strippoli GF; Navaneethan SD; Craig JC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003967. PubMed ID: 17054191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.
    Montero N; Webster AC; Royuela A; Zamora J; Crespo Barrio M; Pascual J
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD007669. PubMed ID: 25220222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
    Black C; Sharma P; Scotland G; McCullough K; McGurn D; Robertson L; Fluck N; MacLeod A; McNamee P; Prescott G; Smith C
    Health Technol Assess; 2010 Apr; 14(21):1-184. PubMed ID: 20441712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
    Coronado Daza J; Martí-Carvajal AJ; Ariza García A; Rodelo Ceballos J; Yomayusa González N; Páez-Canro C; Loza Munárriz C; Urrútia G
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011122. PubMed ID: 26671531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG CoA reductase inhibitors (statins) for dialysis patients.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Nigwekar SU; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2013 Sep; 2013(9):CD004289. PubMed ID: 24022428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentoxifylline for diabetic kidney disease.
    Shan D; Wu HM; Yuan QY; Li J; Zhou RL; Liu GJ
    Cochrane Database Syst Rev; 2012 Feb; (2):CD006800. PubMed ID: 22336824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.